Characterization of Lophomonas spp. Infection in a Population of Critical Care Patients
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Appendix B
Patient | Age | Sex | Diagnosis at Admission | Diagnosis of Lophomonas Infection | Immunologic Status | Clinical Findings | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Initiation of Symptoms | Other Organisms | Diagnostic Delay (Days) | Steroid Use (in mg) * | Other Immuno-Suppressive Drugs | Relevant Background | Fever | Sputum | Respiratory Insufficiency (Pa/FiO2) | Hemodynamic Instability | ||||
#1 | 70 | M | SARS-CoV-2 pneumonia | ICU (after SARS-CoV-2 resolution) | No | 20 | 3706 | No | No | Yes | Yes | Yes (180) | No |
#2 | 85 | M | CAP | Community | No | 11 | No | No | No | No | Yes | Yes (110) | No |
#3 | 54 | M | SARS-CoV-2 pneumonia | ICU (after SARS-CoV-2 resolution) | No | 6 | 1020 | No | T2DM | No | Yes | Yes (228) | Yes |
#4 | 65 | F | SARS-CoV-2 pneumonia | ICU (after SARS-CoV-2 resolution) | No | 8 | 4670 | No | B-cell non-Hodgkin lymphoma | Yes | Yes | Yes (171) | No |
#5 | 62 | F | CAP | Ward (hematology) | CMV | 14 | No | BMT | IgA-lambda myeloma | Yes | Yes | Yes (130) | Yes |
#6 | 80 | F | SARS-CoV-2 pneumonia | ICU (after SARS-CoV-2 resolution) | No | 5 | 350 | Inhaled budesonide | No | Yes | No | Yes (283) | No |
#7 | 82 | F | CAP | Community | No | 18 | 3653 | No | SLE, T2DM | No | No | Yes (235) | No |
#8 | 69 | F | CAP | Community | No | 7 | No | Azacitinidine Citarabine Hydroxyurea | AML | Yes | Yes | Yes (129) | Yes |
#9 | 58 | F | Lung abscess | Community | K. pneumoniae Aspergillus sp. | 12 | 2661 | Everolimus Mycophenolic acid | Heart transplant | Yes | Yes | No (357) | No |
#10 | 39 | F | Fulminant myocarditis | ICU | Staphylococcus aureus | 10 | No | No | No | Yes | Yes | Yes (112) | No |
#11 | 59 | F | SARS-CoV-2 pneumonia | ICU (after SARS-CoV-2 resolution) | Para-influenza type 3 | 6 | 813 | Rituximab Cyclophosphamide Doxorubicin Vincristine | B-cell non-Hodgkin lymphoma | Yes | Yes | Yes (83) | No |
Appendix C
Patient | Laboratory Findings | Radiologic Findings (Chest CT) | Metronidazole Treatment | Outcome | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Leuko-cytes (×109/L) | Neutrophils (×109/L) | Eosinophils (×109/L) | CRP (mg/dL) | PCT (ng/mL) | Lung Consolidation | Ground Glass Opacities | Peri-Bronchial Infiltrates | Abscess | Pleural Effusion | Dose (mg) | Duration (Days) | Complications | Survival | |
#1 | 13,700 | 9250 | 1800 | 14.5 | 0.10 | Yes | Yes | No | No | No | 1000 | 7 | No | Yes |
#2 | 22,100 | 20,000 | 1560 | 18.1 | 0.60 | Yes | Yes | No | No | No | 1000 | 10 | No | Yes |
#3 | 23,300 | 20,600 | 470 | 7.93 | 0.04 | No | No | Yes | No | No | 500 | 7 | No | Yes |
#4 | 13,000 | 12,300 | 30 | 3.39 | 0.09 | No | No | Yes | No | No | 1000 | 7 | Pneumo-mediastinum | Yes |
#5 | 5300 | 4900 | 170 | 29.35 | 0.70 | No | No | Yes | No | Yes | 1000 | 7 | No | Yes |
#6 | 19,700 | 12,600 | 2400 | 7.56 | 0.40 | No | No | No | No | No | 500 | 7 | No | Yes |
#7 | 9800 | 8170 | 60 | 18.0 | 1.20 | No | Yes | No | No | Yes | 1000 | 10 | No | Yes |
#8 | 62,300 | 19,900 | 620 | 8.4 | 0.46 | No | No | Yes | No | Yes | 1000 | 21 | No | Yes |
#9 | 38,300 | 34,400 | 2030 | 46.6 | 10.30 | Yes | Yes | No | Yes | No | 750 | 25 | Persistent lung infection | No |
#10 | 24,000 | 20,000 | 500 | 6 | 4.60 | No | No | Yes | No | Yes | 500 | 7 | No | Yes |
#11 | 1700 | 1590 | 60 | 4.88 | 0.08 | No | Yes | Yes | No | No | 500 | 14 | No | Yes |
References
- Martinez-Girón, R.; Cornelis Van Woerden, H. Lophomonas blattarum and bronchopulmonary disease. J. Med. Microbiol. 2013, 62, 1641–1648. [Google Scholar] [CrossRef]
- Chaudhury, A.; Parija, S.C. Lophomonas blattarum: A new flagellate causing respiratory tract infections. Trop. Parasitol. 2020, 10, 7–11. [Google Scholar] [CrossRef]
- Mokhtarian, K.; Taghipour, S.; Nakhaei, M.; Taheri, A.; Sharifpour, A.; Fakhar, M.; Ziaei Hezarjaribi, H. Molecular Evidence of Emerged Pulmonary Lophomoniasis due to Lophomonas blattarum among Hospitalized Patients in Southwestern Iran: A National Registry-Based Study. Interdiscip. Perspect. Infect. Dis. 2022, 2022, 6292823. [Google Scholar] [CrossRef]
- Ding, Q.; Shen, K. Pulmonary Infection with Lophomonas blattarum. Indian J. Pediatr. 2021, 88, 23–27. [Google Scholar] [CrossRef]
- Van Woerden, H.C.; Martínez-Girón, R.; Martínez-Torre, C. Protozoan Cysts in Faecal Pellets of German Cockroaches (Blattella germanica), with Particular Emphasis on Lophomonas blattarum. Acta Parasitol. 2020, 65, 831–836. [Google Scholar] [CrossRef]
- Van Woerden, H.C.; Martinez-Giron, R. Lophomonas blattarum: Is it Only its Morphology that Prevents its Recognition? Chin. Med. J. 2017, 130, 117. [Google Scholar] [CrossRef]
- Berenji, F.; Parian, M.; Fata, A.; Bakhshaee, M.; Fattahi, F. First Case Report of Sinusitis with Lophomonas blattarum from Iran. Case Rep. Infect. Dis. 2016, 2016, 2614187. [Google Scholar] [CrossRef] [PubMed]
- Bakhshaee, M.; Teimouri, Y.; Jabbari Azad, F.; Yousefi, R.; Parian, M.; Berenji, F. Detection of Lophomonas blattarum (Order: Hypermastigida) from Iranian Patients with Allergic Rhinitis. IJPA [Internet]. 11 December 2022. Available online: https://publish.kne-publishing.com/index.php/IJPA/article/view/11286 (accessed on 11 June 2023).
- Fakhar, M.; Nakhaei, M.; Sharifpour, A.; Kalani, H.; Banimostafavi, E.S.; Abedi, S.; Safanavaei, S.; Aliyali, M. First Molecular Diagnosis of Lophomoniasis: The End of a Controversial Story. Acta Parasitol. 2019, 64, 390–393. [Google Scholar] [CrossRef] [PubMed]
- Vila, J.; Martínez, J.A. Opportunistic Infections in the Intensive Care Unit: A Microbiologic Overview. In Infectious Diseases in Critical Care; Rello, J., Kollef, M., Díaz, E., Rodríguez, A., Eds.; Springer: Berlin/Heidelberg, Germany, 2007; pp. 29–34. [Google Scholar] [CrossRef]
- Nakhaei, M.; Fakhar, M.; Sharifpour, A.; Banimostafavi, E.S.; Zakariaei, Z.; Mehravaran, H.; Saberi, R.; Safanavaei, S.; Abedi, S.; Aliyali, M.; et al. First Co-morbidity of Lophomonas blattarum and COVID-19 Infections: Confirmed Using Molecular Approach. Acta Parasitol. 2022, 67, 535–538. [Google Scholar] [CrossRef] [PubMed]
- Failoc-Rojas, V.E.; Iglesias-Osores, S.; Silva-Díaz, H. Lophomonas sp. in the upper and lower respiratory tract of patients from a hospital in Lambayeque, Peru: Clinical case studies. Respir. Med. Case Rep. 2020, 31, 101142. [Google Scholar] [CrossRef] [PubMed]
- Zieleskiewicz, L.; Chiche, L.; Donati, S.; Piarroux, R. Strongyloidiasis in Intensive Care. In Uncommon Diseases in the ICU; Leone, M., Martin, C., Vincent, J.L., Eds.; Springer International Publishing: Cham, Switzerland, 2014; pp. 61–68. [Google Scholar] [CrossRef]
- Alam-Eldin, Y.H.; Abdulaziz, A.M. Identification criteria of the rare multi-flagellate Lophomonas blattarum: Comparison of different staining techniques. Parasitol. Res. 2015, 114, 3309–3314. [Google Scholar] [CrossRef] [PubMed]
- He, Q.; Chen, X.; Lin, B.; Qu, L.; Wu, J.; Chen, J. Late Onset Pulmonary Lophomonas blattarum Infection in Renal Transplantation: A Report of Two Cases. Intern. Med. 2011, 50, 1039–1043. [Google Scholar] [CrossRef]
- Yao, G.; Zhou, B.; Zeng, L. Imaging Characteristics of Bronchopulmonary Lophomonas blattarum Infection: Case Report and Literature Review. J. Thorac. Imaging 2009, 24, 49–51. [Google Scholar] [CrossRef]
- Leitsch, D. A review on metronidazole: An old warhorse in antimicrobial chemotherapy. Parasitology 2019, 146, 1167–1178. [Google Scholar] [CrossRef] [PubMed]
- Mirzaei, R.; Goodarzi, P.; Asadi, M.; Soltani, A.; Aljanabi, H.A.A.; Jeda, A.S.; Dashtbin, S.; Jalalifar, S.; Mohammadzadeh, R.; Teimoori, A.; et al. Bacterial co-infections with SARS-CoV-2. IUBMB Life 2020, 72, 2097–2111. [Google Scholar] [CrossRef]
- Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020, 71, 2459–2468. [Google Scholar] [CrossRef]
- Chen, X.; Liao, B.; Cheng, L.; Peng, X.; Xu, X.; Li, Y.; Hu, T.; Li, J.; Zhou, X.; Ren, B. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol. 2020, 104, 7777–7785. [Google Scholar] [CrossRef]
- Araújo, C.P.; Trindade, A.F.D.; Oliveira, G.G.; Araújo, P.S.R.D.; Souza, G.L.O.D. Identificação de Lophomonas spp em lavado broncoalveolar de indivíduo portador de SRAG por SARS-CoV-2 associado a tuberculose pulmonar. RSD 2022, 11, e46211222808. [Google Scholar] [CrossRef]
- Verma, S.; Verma, G.; Singh, D.V.; Mokta, J.; Negi, R.S.; Jhobta, A.; Kanga, A. Dual infection with pulmonary tuberculosis and Lophomonas blattarum in India. Int. J. Tuberc. Lung Dis. 2015, 19, 368–369. [Google Scholar] [CrossRef]
- Tyagi, R.; Anand, K.; Teple, K.; Negi, R. Lophomonas blattarum infection in immunocompetent patient. Lung India 2016, 33, 667. [Google Scholar] [CrossRef]
- Li, R.; Gao, Z.-C. Lophomonas blattarum Infection or Just the Movement of Ciliated Epithelial Cells? Chin. Med. J. 2016, 129, 739–742. [Google Scholar] [CrossRef] [PubMed]
- Saldaña, N.G.; Javier, F.O.M.; Larrauri, F.R.; Trujillo, D.M.G.; Montoya, E.V.; De La Garza, E.A.; Olguín, H.J. Bronchopulmonary infection by Lophomonas blattarum in a pediatric patient after hematopoietic progenitor cell transplantation: First report in Mexico. J. Thorac. Dis. 2017, 9, E899–E902. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
das Neves Coelho, F.; Borralho, J.; Baptista-Fernandes, T.; Toscano, C.; Carmo, M.E. Characterization of Lophomonas spp. Infection in a Population of Critical Care Patients. Infect. Dis. Rep. 2024, 16, 83-92. https://doi.org/10.3390/idr16010006
das Neves Coelho F, Borralho J, Baptista-Fernandes T, Toscano C, Carmo ME. Characterization of Lophomonas spp. Infection in a Population of Critical Care Patients. Infectious Disease Reports. 2024; 16(1):83-92. https://doi.org/10.3390/idr16010006
Chicago/Turabian Styledas Neves Coelho, Francisco, João Borralho, Teresa Baptista-Fernandes, Cristina Toscano, and Maria Eduarda Carmo. 2024. "Characterization of Lophomonas spp. Infection in a Population of Critical Care Patients" Infectious Disease Reports 16, no. 1: 83-92. https://doi.org/10.3390/idr16010006
APA Styledas Neves Coelho, F., Borralho, J., Baptista-Fernandes, T., Toscano, C., & Carmo, M. E. (2024). Characterization of Lophomonas spp. Infection in a Population of Critical Care Patients. Infectious Disease Reports, 16(1), 83-92. https://doi.org/10.3390/idr16010006